Sleep apnea will be a particular focus among the pulmonary medicine topics at the 27th annual SLEEP meeting here.
Of the more than 1,300 abstracts, the majority of respiratory sleep medicine research to be presented will address the consequences, treatment, and management of obstructive sleep apnea (OSA).
One such study by Dennis Auckley, MD, of MetroHealth Medical Center at Case Western University in Cleveland, Ohio, and colleagues, showed that validated questionnaires offered reasonable positive predictive value but poor negative predictive value in hospitalized patients as a screen for sleep apnea.
Also to be presented will be studies involving treatments for sleep disordered breathing in children, including impacts on sudden infant death syndrome in premature infants and sleep extension in adolescents with asthma.
Research presented at the meeting will include: Relationships between total body fat and apnea-hypopnea index in obese patientsImpaired driving in patients with sleep apneaAssociations between respiratory-related leg movements and cardiovascular eventsThe effect of continuous positive airway pressure on glycemic control in patients with diabetesZonisamide treatment in overweight and obese patients with sleep apnea and hypopneaReduction of cerebral oxygenation in premature infants who sleep in the prone positionThe feasibility of experimentally manipulated sleep extension in teens with asthmaDose-response deterioration of overnight endothelial function in children with obstructive sleep apneaSevere obstructive sleep apnea's association with poor blood pressure control in spite of antihypertensive drug use
Little of the research presented regarding airway obstruction and other pulmonary sleep conditions incorporates new drugs or treatments or phase III data, though one study does look at the effects of zonisamide treatment for obese patients with sleep apnea.
The study was supported by Teva Pharmaceuticals.
